Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide versus ADT in hormone-naive prostate cancer
2016-004334-17Phase 2Active
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: PSA response at 24 weeks. Started Apr 2017; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-004334-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004334-17.